Sveinung Wergeland Sorbye
Overview
Explore the profile of Sveinung Wergeland Sorbye including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jorgensen A, Simonsen G, Sorbye S
Vaccines (Basel)
. 2025 Jan;
13(1).
PMID: 39852875
Background/objectives: Human papillomavirus (HPV) is the primary cause of high-grade cervical lesions and cervical cancer worldwide. In Norway, HPV vaccination was introduced in 2009 for seventh-grade girls and extended through...
2.
Flores C, Falang B, Gomez-Laguna L, Gutierrez G, Leon J, Uribe M, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001547
Cervical cancer remains a significant public health issue, particularly in regions with low screening uptake. This study evaluates the effectiveness of self-sampling and the 7-type HPV mRNA E6/E7 test in...
3.
Rykkelid M, Wennberg H, Richardsen E, Sorbye S
Pathogens
. 2024 May;
13(5).
PMID: 38787233
Human papillomavirus (HPV) is associated with cellular changes in the cervix leading to cancer, which highlights the importance of vaccination in preventing HPV infections and subsequent cellular changes. Women undergoing...
4.
Mikalsen M, Simonsen G, Sorbye S
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675803
Background: Human papillomavirus (HPV), the most prevalent sexually transmitted infection globally, is a key risk factor for high-grade cervical lesions and cervical cancer. Since 2009, HPV vaccination has been part...
5.
Sorbye S, Falang B, Botha M, Snyman L, van der Merwe H, Visser C, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001713
Background: Cervical cancer prevention in regions with limited access to screening and HPV vaccination necessitates innovative approaches. This study explored the potential of a test-and-treat strategy using mRNA HPV tests...
6.
Rad A, Sorbye S, Tiwari S, Lochen M, Skjeldestad F
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370716
Background: The study's purpose was to evaluate the performance of a five-type HPV mRNA test to predict cervical intraepithelial neoplasia grade 3 or worse (CIN3+) during up to 12 years...
7.
Skjeldestad F, Sorbye S
Int J Environ Res Public Health
. 2023 Mar;
20(6).
PMID: 36981655
Background: The Norwegian Cervical Cancer Screening Programme recommends that women treated for cervical intraepithelial neoplasia (CIN) only be returned to 3-year screening after receiving two consecutive negative co-tests, 6 months...
8.
Rad A, Sorbye S, Brenn T, Tiwari S, Lochen M, Skjeldestad F
Int J Environ Res Public Health
. 2023 Mar;
20(5).
PMID: 36901129
Background: A specific, cost-effective triage test for minor cytological abnormalities is essential for cervical cancer screening among younger women to reduce overmanagement and unnecessary healthcare utilization. We compared the triage...
9.
Al-Shibli K, Mohammed H, Maurseth R, Fostervold M, Werner S, Sorbye S
PLoS One
. 2022 Nov;
17(11):e0275858.
PMID: 36413537
Background: Despite a well-established cervical cancer (CC) screening program in Norway, the incidence of CC in young women is increasing, peaking at 35 years of age. 25 percent of all...
10.
Nestegard O, Moayeri B, Halvorsen F, Tonnesen T, Sorbye S, Paulssen E, et al.
PLoS One
. 2022 Apr;
17(4):e0265322.
PMID: 35442962
Background: Increasing prevalence of antibiotic resistance especially to clarithromycin and metronidazole has been observed in Helicobacter pylori (H. pylori). Aim: To characterize the antimicrobial resistance pattern of H. pylori before...